HFS
INDV icon

Hantz Financial Services’s Indivior Pharmaceuticals INDV Stock Holding History

Hantz Financial Services’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed – – 2529
2025
Q4 		$0 Buy
+7
New +$214 ﹤0.01% 2472

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hantz Financial Services's INDV Position: Q1 2026 in Review

Hantz Financial Services sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 7 shares.

Hantz Financial Services first reported a position in INDV in Q4 2025 and held it in 1 quarter. The position peaked at $0 in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Hantz Financial Services reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hantz Financial Services sold 7 Indivior Pharmaceuticals shares in Q1 2026.
  • Hantz Financial Services first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Hantz Financial Services's Indivior Pharmaceuticals position peaked at $0 in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.